US FDA Continues Cannabinoid Analysis Required In FY2021 Budget
FDA is testing cannabidiol and other cannabinoids for whether labeled amounts match what’s in a product, says CFSAN Deputy Director Doug Stearn. The work is supported with $5m provided in the agency’s FY21 appropriation.
You may also be interested in...
Congressional Research Service report says in addition to markets for hemp from fiber, seeds and flowers, “a separate, marketable category exists for the plant’s extracted compounds.” Ingredients from hemp seeds and grains as well as from flowers are alternative protein sources in supplements, foods and beverages and dairy alternatives.
FDA commissioner should be announced by mid-November and will likely continue to prioritize food and supplement safety, propelled by contaminants found in baby food, say two attorneys with Alston & Bird. A regulatory pathway for cannabidiol also is expected to be a priority once a commissioner is named.
Royal DSM and Colorado’s Mile High Labs partner to provide companies in supplement, food and beverage sectors with ingredients to develop formulations with CBD and other cannabinoids. They initially are targeting the US and look to enter Canada, South America, Europe and Australia.